BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191206T080000
DTEND;TZID=America/New_York:20191206T170000
DTSTAMP:20260715T042319
CREATED:20191122T165805Z
LAST-MODIFIED:20191122T165805Z
UID:7305-1575619200-1575651600@scienceinboston.com
SUMMARY:Yale Lifesciences Pitchfest
DESCRIPTION:Overview\n\nYale Lifesciences Pitchfest is a full day where the top 32 biotech opportunities developing within Yale take the stage to present their 5-minute pitches to industry. The 32 presenting investigators will be competing for $4500 in prizes to be awarded at the end of the day\, but\, more importantly\, all advance as semifinalists in the annual Blavatnik Fund for Innovation at Yale competition\, which will make nearly $3 million in awards in May 2020. \nYale Lifesciences Pitchfest is presented by the Blavatnik Fund for Innovation at Yale.  The Blavatnik Fund helps to accelerate the development of important early-stage discoveries in the life sciences into medical or commercial applications by awarding pilot grants to support exploratory and proof-of-concept activities\, as well as larger development grants for more established projects.  Over its first three years\, the fund has made 21 awards for Yale projects totaling $5 million. \nFor more info see: \nhttps://blavatnik.ocr.yale.edu
URL:https://scienceinboston.com/event/yale-lifesciences-pitchfest/
LOCATION:Alexion Pharmaceuticals\, 100 College St\, New Haven\, CT\, 06510\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191206T080000
DTEND;TZID=America/New_York:20191206T170000
DTSTAMP:20260715T042319
CREATED:20191122T165805Z
LAST-MODIFIED:20191122T165805Z
UID:27398-1575619200-1575651600@scienceinboston.com
SUMMARY:Yale Lifesciences Pitchfest
DESCRIPTION:Overview\n\nYale Lifesciences Pitchfest is a full day where the top 32 biotech opportunities developing within Yale take the stage to present their 5-minute pitches to industry. The 32 presenting investigators will be competing for $4500 in prizes to be awarded at the end of the day\, but\, more importantly\, all advance as semifinalists in the annual Blavatnik Fund for Innovation at Yale competition\, which will make nearly $3 million in awards in May 2020. \nYale Lifesciences Pitchfest is presented by the Blavatnik Fund for Innovation at Yale.  The Blavatnik Fund helps to accelerate the development of important early-stage discoveries in the life sciences into medical or commercial applications by awarding pilot grants to support exploratory and proof-of-concept activities\, as well as larger development grants for more established projects.  Over its first three years\, the fund has made 21 awards for Yale projects totaling $5 million. \nFor more info see: \nhttps://blavatnik.ocr.yale.edu
URL:https://scienceinboston.com/event/yale-lifesciences-pitchfest-2/
LOCATION:Alexion Pharmaceuticals\, 100 College St\, New Haven\, CT\, 06510\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T080000
DTEND;TZID=America/New_York:20191208T120000
DTSTAMP:20260715T042319
CREATED:20191122T170001Z
LAST-MODIFIED:20191122T170001Z
UID:7309-1575792000-1575806400@scienceinboston.com
SUMMARY:Jingle Bell Run
DESCRIPTION:Overview\n\nThe Jingle Bell Run is a fun\, festive race. Together\, we’ll jingle all the way to a cure – and have a fantastic time every step we take!\nBring your friends & family to run or walk and support 1.2 million Massachusetts residents\, including nearly 6\,000 children living with the pain of arthritis.\nGet your jingle on!
URL:https://scienceinboston.com/event/jingle-bell-run/
LOCATION:Boston Common\, Boston Common Corner of Beacon & Charles St.\, Boston\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T080000
DTEND;TZID=America/New_York:20191208T120000
DTSTAMP:20260715T042319
CREATED:20191122T170001Z
LAST-MODIFIED:20191122T170001Z
UID:27399-1575792000-1575806400@scienceinboston.com
SUMMARY:Jingle Bell Run
DESCRIPTION:Overview\n\nThe Jingle Bell Run is a fun\, festive race. Together\, we’ll jingle all the way to a cure – and have a fantastic time every step we take!\nBring your friends & family to run or walk and support 1.2 million Massachusetts residents\, including nearly 6\,000 children living with the pain of arthritis.\nGet your jingle on!
URL:https://scienceinboston.com/event/jingle-bell-run-2/
LOCATION:Boston Common\, Boston Common Corner of Beacon & Charles St.\, Boston\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T113000
DTEND;TZID=America/New_York:20191208T140000
DTSTAMP:20260715T042319
CREATED:20191125T220140Z
LAST-MODIFIED:20191125T220314Z
UID:7360-1575804600-1575813600@scienceinboston.com
SUMMARY:Frontiers in HIV: Sailing in the Scientific Perspective
DESCRIPTION:When HIV first began infecting humans in the 1970s\, scientists were unaware of its existence. Now\, more than 35 million people across the globe live with HIV/AIDS. The medical community\, politicians and support organizations have made incredible progress in the fight against this formerly unknown and heavily stigmatized virus. Despite the fact that infection rates have fallen or stabilized in many countries across the world\,we still have a long way to go. \nCurrent estimates point to the number of HIV-positive patients in treatment exceeding the number of new infections. Throughout its history\, the number of new infections has always outweighed the number of patients in treatment. In light of this new data\, it looks like scientists may finally take the lead in the battle against the global AIDS epidemic. \nRecent scientific advances have brought us closer to the elusive goal of an AIDS vaccine\, but reaching that goal will require broad collaboration to adapt breakthroughs in the sciences that cultivate an understanding of the interactions between HIV and the immune system. \nWith World AIDS Day \, approaching on December 1st\, ECUSA would like to highlight the current advances in HIV research. For this reason\,we have invited 4 highly recognized researchers who stand for the fight against infection. \nDr. Maria Duenas Decamp is an Assistant Professor at UMASS Medical school. She graduated from Universidad Complutense de Madrid and obtained her Ph.D. in Universidad Autónoma de Madrid. Before moving to the USA\, she was a research fellow in the Centro de Investigación Básica de España\, Merck Sharp & Dohme in Spain. She has a broad background in Human immunodeficiency virus type 1 (HIV-1) with specific expertise in areas including HIV-1 tropism\, neutralization\, evolution\, fitness\, and resistance to antiretroviral drugs. She has studied HIV-1 envelopes derived from brain and lymph node tissues to map determinants of macrophage-tropism and sensitivity to neutralizing antibodies (NAbs). She has found new amino acids in specific positions implicated in gp120 structural changes that affect the accessibility of some important regions in the trimer to NAbs. These determinants will be used to develop future immunogens that elicit broadly potent NAbs. Dr. Duenas Decamp has been awarded an R21 and an R01 for this project. She has also been interested in the role of hematopoietic progenitor cells in HIV pathogenesis and in contributing to HIV viral reservoirs in vivo. She was awarded a CFAR Developmental Pilot grant\, and the project was also funded by NIH. \nDr. Fatema Z. Chowdhury (Navin) is a Senior Research Scientist at the Ragon Institute of MGH\, MIT and Harvard in Cambridge. She comes from a diverse scientific training background starting with her undergraduate published studies in bacterial physiology using competitive colonization of mouse intestine by E. coli as a model. She subsequently earned her PhD in Immunology at UT Southwestern Medical Center\, where she published her studies of how innate inflammatory cytokines regulate CD8+ T cell function\, both in mice and humans. She is interested in further studying host-pathogen interaction and joined the Ragon Institute as a postdoctoral fellow in 2014 to study HIV-1 pathogenesis and immunity. She has always been very active in outreach as well\, such as participating in fundraising events raising awareness about HIV and AIDS in the community. \nDr. Andrew J. Anderson did his Ph.D. at the University of California\, Riverside\, in Kenneth Dorshkind’s lab\, where he studied how bone marrow microenvironments influence B lymphocyte development. He then moved to Columbia University\, to work in Kathryn Calame’s lab and focused on T cell-specific gene expression. During this time\, he began exploring how cell-specific transcription factors influence HIV replication\, which has been the primary focus of his research as an independent investigator. His first position as an independent investigator was at Penn State University in the Department of Veterinary and Biomedical Sciences\, where activities included being a co-director of the Immunobiology Graduate Program\, Director of the Immunology and Infectious Diseases Undergraduate Program and Director of the Center for Immunology and Infectious Diseases. He moved to Boston University School of Medicine\, Department of Medicine and Section of Infectious Diseases in 2007\, and his institutional activities include Assistant Dean of Graduate Medical Sciences\, Co-director of the Providence/Boston Center for AIDS Research\, Director of the BU PREP post-Bac program and developing international training programs. \nDr. Daniel Claiborne is a senior postdoctoral fellow in the laboratory of Dr. Todd Allen at the Ragon Institute of MGH\, MIT\, and Harvard. In 2014 he received his Ph.D. in Immunology and Molecular Pathogenesis from Emory University. During his graduate work\, he helped to define the integral role of transmitted viral characteristics\, such as replicative capacity\, in determining many aspects of HIV-associated pathogenesis and the severity of disease progression. His current work focuses on understanding the potential for novel gene therapy approaches\, including CAR T cell therapy\, to control HIV\, as well as identifying the host and viral factors influencing the selection of transmitted/founder viruses during the HIV-1 transmission bottleneck and the trajectory of disease progression thereafter. \nLogistics for the event: \n11.30-11.40: Event aperture and welcoming \n11.40-12.10: Cells at the service of HIV: Cytotoxic responses to infection\, by Dr. Fatema Z. Chowdhury \n12.10-12.40: HIV models: the use of humanized mice\, by Dr. Daniel Clairborne \n12.40-13.00: Break with light appetizers and coffee \n13.00-13.30: New therapeutic target: Research on effective vaccines\, by Dr. Maria J. Duenas-Decamp \n13.30-14.00: Today HIV latency: Barrier to an effective cure\, by Dr. Andrew J. Henderson \n14.00-14.05: Event closure \nFree event. Limited space. Registration required.
URL:https://scienceinboston.com/event/frontiers-in-hiv-sailing-in-the-scientific-perspective/
LOCATION:MIT Building E51\, MIT Building E51\, 70 Memorial Drive Cambridge\, MA 02142\, Boston\, MA\, 02141\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2019/11/Capture.png
ORGANIZER;CN="ECUSA":MAILTO:boston@ecusa.es
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T113000
DTEND;TZID=America/New_York:20191208T140000
DTSTAMP:20260715T042319
CREATED:20191125T220140Z
LAST-MODIFIED:20191125T220140Z
UID:27411-1575804600-1575813600@scienceinboston.com
SUMMARY:Frontiers in HIV: Sailing in the Scientific Perspective
DESCRIPTION:When HIV first began infecting humans in the 1970s\, scientists were unaware of its existence. Now\, more than 35 million people across the globe live with HIV/AIDS. The medical community\, politicians and support organizations have made incredible progress in the fight against this formerly unknown and heavily stigmatized virus. Despite the fact that infection rates have fallen or stabilized in many countries across the world\,we still have a long way to go. \nCurrent estimates point to the number of HIV-positive patients in treatment exceeding the number of new infections. Throughout its history\, the number of new infections has always outweighed the number of patients in treatment. In light of this new data\, it looks like scientists may finally take the lead in the battle against the global AIDS epidemic. \nRecent scientific advances have brought us closer to the elusive goal of an AIDS vaccine\, but reaching that goal will require broad collaboration to adapt breakthroughs in the sciences that cultivate an understanding of the interactions between HIV and the immune system. \nWith World AIDS Day \, approaching on December 1st\, ECUSA would like to highlight the current advances in HIV research. For this reason\,we have invited 4 highly recognized researchers who stand for the fight against infection. \nDr. Maria Duenas Decamp is an Assistant Professor at UMASS Medical school. She graduated from Universidad Complutense de Madrid and obtained her Ph.D. in Universidad Autónoma de Madrid. Before moving to the USA\, she was a research fellow in the Centro de Investigación Básica de España\, Merck Sharp & Dohme in Spain. She has a broad background in Human immunodeficiency virus type 1 (HIV-1) with specific expertise in areas including HIV-1 tropism\, neutralization\, evolution\, fitness\, and resistance to antiretroviral drugs. She has studied HIV-1 envelopes derived from brain and lymph node tissues to map determinants of macrophage-tropism and sensitivity to neutralizing antibodies (NAbs). She has found new amino acids in specific positions implicated in gp120 structural changes that affect the accessibility of some important regions in the trimer to NAbs. These determinants will be used to develop future immunogens that elicit broadly potent NAbs. Dr. Duenas Decamp has been awarded an R21 and an R01 for this project. She has also been interested in the role of hematopoietic progenitor cells in HIV pathogenesis and in contributing to HIV viral reservoirs in vivo. She was awarded a CFAR Developmental Pilot grant\, and the project was also funded by NIH. \nDr. Fatema Z. Chowdhury (Navin) is a Senior Research Scientist at the Ragon Institute of MGH\, MIT and Harvard in Cambridge. She comes from a diverse scientific training background starting with her undergraduate published studies in bacterial physiology using competitive colonization of mouse intestine by E. coli as a model. She subsequently earned her PhD in Immunology at UT Southwestern Medical Center\, where she published her studies of how innate inflammatory cytokines regulate CD8+ T cell function\, both in mice and humans. She is interested in further studying host-pathogen interaction and joined the Ragon Institute as a postdoctoral fellow in 2014 to study HIV-1 pathogenesis and immunity. She has always been very active in outreach as well\, such as participating in fundraising events raising awareness about HIV and AIDS in the community. \nDr. Andrew J. Anderson did his Ph.D. at the University of California\, Riverside\, in Kenneth Dorshkind’s lab\, where he studied how bone marrow microenvironments influence B lymphocyte development. He then moved to Columbia University\, to work in Kathryn Calame’s lab and focused on T cell-specific gene expression. During this time\, he began exploring how cell-specific transcription factors influence HIV replication\, which has been the primary focus of his research as an independent investigator. His first position as an independent investigator was at Penn State University in the Department of Veterinary and Biomedical Sciences\, where activities included being a co-director of the Immunobiology Graduate Program\, Director of the Immunology and Infectious Diseases Undergraduate Program and Director of the Center for Immunology and Infectious Diseases. He moved to Boston University School of Medicine\, Department of Medicine and Section of Infectious Diseases in 2007\, and his institutional activities include Assistant Dean of Graduate Medical Sciences\, Co-director of the Providence/Boston Center for AIDS Research\, Director of the BU PREP post-Bac program and developing international training programs. \nDr. Daniel Claiborne is a senior postdoctoral fellow in the laboratory of Dr. Todd Allen at the Ragon Institute of MGH\, MIT\, and Harvard. In 2014 he received his Ph.D. in Immunology and Molecular Pathogenesis from Emory University. During his graduate work\, he helped to define the integral role of transmitted viral characteristics\, such as replicative capacity\, in determining many aspects of HIV-associated pathogenesis and the severity of disease progression. His current work focuses on understanding the potential for novel gene therapy approaches\, including CAR T cell therapy\, to control HIV\, as well as identifying the host and viral factors influencing the selection of transmitted/founder viruses during the HIV-1 transmission bottleneck and the trajectory of disease progression thereafter. \nLogistics for the event: \n11.30-11.40: Event aperture and welcoming \n11.40-12.10: Cells at the service of HIV: Cytotoxic responses to infection\, by Dr. Fatema Z. Chowdhury \n12.10-12.40: HIV models: the use of humanized mice\, by Dr. Daniel Clairborne \n12.40-13.00: Break with light appetizers and coffee \n13.00-13.30: New therapeutic target: Research on effective vaccines\, by Dr. Maria J. Duenas-Decamp \n13.30-14.00: Today HIV latency: Barrier to an effective cure\, by Dr. Andrew J. Henderson \n14.00-14.05: Event closure \nFree event. Limited space. Registration required.
URL:https://scienceinboston.com/event/frontiers-in-hiv-sailing-in-the-scientific-perspective-2/
LOCATION:MIT Building E51\, MIT Building E51\, 70 Memorial Drive Cambridge\, MA 02142\, Boston\, MA\, 02141\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2019/11/Capture.png
ORGANIZER;CN="ECUSA":MAILTO:boston@ecusa.es
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T042319
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:7324-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T042319
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:27400-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry-2/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260715T042319
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:7328-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260715T042319
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:27401-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T042319
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155733Z
UID:7330-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T042319
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155713Z
UID:27402-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models-2/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260715T042319
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:7334-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260715T042319
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:27403-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T080000
DTEND;TZID=America/New_York:20191211T100000
DTSTAMP:20260715T042319
CREATED:20191125T160127Z
LAST-MODIFIED:20191125T160127Z
UID:7336-1576051200-1576058400@scienceinboston.com
SUMMARY:Building A Bulletproof Communications & Crisis Management Strategy
DESCRIPTION:How to navigate a crisis? In a time characterized by online activism and hyper-polarization\, where health is politicized and corporate America is scrutinized\, the potential for a crisis lurks in the shadows for every healthcare company. No matter the size or specialty\, every company has its own unique set of risks\, some of which are predictable and many of which are not. \nSo how do you identify and mitigate risks early\, before a company’s crisis has made it to the front page of the Wall Street Journal? And how do you find the resources and time for that work when your team is small and already busy? \nJoin us for a lively discussion with cross-functional leaders on how companies can identify and plan for the issues that are relevant to their business. Whether it’s avoiding a social media firestorm\, managing grassroots activism from patients advocates\, or navigating data privacy issues; our esteemed panelists will be ready to share their experiences and answer your questions based on their vast array of experiences. \nSponsored by the Marketing Communications (MARCOM) Forum Working Group.
URL:https://scienceinboston.com/event/building-a-bulletproof-communications-crisis-management-strategy/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T080000
DTEND;TZID=America/New_York:20191211T100000
DTSTAMP:20260715T042319
CREATED:20191125T160127Z
LAST-MODIFIED:20191125T160127Z
UID:27404-1576051200-1576058400@scienceinboston.com
SUMMARY:Building A Bulletproof Communications & Crisis Management Strategy
DESCRIPTION:How to navigate a crisis? In a time characterized by online activism and hyper-polarization\, where health is politicized and corporate America is scrutinized\, the potential for a crisis lurks in the shadows for every healthcare company. No matter the size or specialty\, every company has its own unique set of risks\, some of which are predictable and many of which are not. \nSo how do you identify and mitigate risks early\, before a company’s crisis has made it to the front page of the Wall Street Journal? And how do you find the resources and time for that work when your team is small and already busy? \nJoin us for a lively discussion with cross-functional leaders on how companies can identify and plan for the issues that are relevant to their business. Whether it’s avoiding a social media firestorm\, managing grassroots activism from patients advocates\, or navigating data privacy issues; our esteemed panelists will be ready to share their experiences and answer your questions based on their vast array of experiences. \nSponsored by the Marketing Communications (MARCOM) Forum Working Group.
URL:https://scienceinboston.com/event/building-a-bulletproof-communications-crisis-management-strategy-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T080000
DTEND;TZID=America/New_York:20191211T170000
DTSTAMP:20260715T042319
CREATED:20191125T160310Z
LAST-MODIFIED:20191125T160310Z
UID:7338-1576051200-1576083600@scienceinboston.com
SUMMARY:Developing Innovative Leaders in Biotech
DESCRIPTION:Overview\n\nIndividuals and teams drive innovation throughout the biomedical industry\, from discovery research to clinical trials\, product development and the larger market. Because of the risks inherent in this process\, there is great interest in cultivating individual and team behaviors to try to make innovation more systematic. \nIn this webinar\, Jeff Karp\, PhD\, will draw upon his history of bridging academia and industry\, starting six companies (including the newly public Frequency Therapeutics)\, creating multiple products and raising more than $300 million dollars in venture and philanthropic funding. He will discuss ways to encourage creativity and individual empowerment in your team\, and utilize your network to efficiently socialize ideas and identify strategic priorities.
URL:https://scienceinboston.com/event/developing-innovative-leaders-in-biotech/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T080000
DTEND;TZID=America/New_York:20191211T170000
DTSTAMP:20260715T042319
CREATED:20191125T160310Z
LAST-MODIFIED:20191125T160310Z
UID:27405-1576051200-1576083600@scienceinboston.com
SUMMARY:Developing Innovative Leaders in Biotech
DESCRIPTION:Overview\n\nIndividuals and teams drive innovation throughout the biomedical industry\, from discovery research to clinical trials\, product development and the larger market. Because of the risks inherent in this process\, there is great interest in cultivating individual and team behaviors to try to make innovation more systematic. \nIn this webinar\, Jeff Karp\, PhD\, will draw upon his history of bridging academia and industry\, starting six companies (including the newly public Frequency Therapeutics)\, creating multiple products and raising more than $300 million dollars in venture and philanthropic funding. He will discuss ways to encourage creativity and individual empowerment in your team\, and utilize your network to efficiently socialize ideas and identify strategic priorities.
URL:https://scienceinboston.com/event/developing-innovative-leaders-in-biotech-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T173000
DTEND;TZID=America/New_York:20191211T203000
DTSTAMP:20260715T042319
CREATED:20191125T160604Z
LAST-MODIFIED:20191125T160852Z
UID:7340-1576085400-1576096200@scienceinboston.com
SUMMARY:Women in Bio: 2019 Annual Wine & Chocolate Holiday Party
DESCRIPTION:Overview\nThe WIB-Greater Boston chapter will be celebrating the holiday season at The Allsteel on December 11\, 2019\, in Boston. Join us for a night of wine\, chocolate\, and cheer as we bid farewell to 2019 and look ahead to another successful year in the hub! \nTo register\, visit: https://www.womeninbio.org/events/EventDetails.aspx?id=1296476&group= \nProgram \n5:30 p.m. – Registration opens\n5:30 p.m. – 8:30 p.m.: Food\, drinks\, and networking \nPricing Information* \n\nMembers: $15\nNon-Members/Free Unlimited Guest Members*: $30\n\n*To access the Member rate\, click here to purchase a WIB membership. \nSpecial Pricing for Guests \nMembers can register guests at member price. \nWalk-Ins Accepted? \nYes* \n* – Walk-ins will be accepted until event capacity is reached \nMaximum Capacity \n60 \nParking Information \nParking available at State Street garage and other nearby garages. \nDirections from Public Transit \nRed line to State Street
URL:https://scienceinboston.com/event/women-in-bio-2019-annual-wine-chocolate-holiday-party/
LOCATION:Allsteel\, 200 State Street #400\, Boston\, MA\, 02109\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191211T173000
DTEND;TZID=America/New_York:20191211T203000
DTSTAMP:20260715T042319
CREATED:20191125T160604Z
LAST-MODIFIED:20191125T160604Z
UID:27406-1576085400-1576096200@scienceinboston.com
SUMMARY:Women in Bio: 2019 Annual Wine & Chocolate Holiday Party
DESCRIPTION:Overview\nThe WIB-Greater Boston chapter will be celebrating the holiday season at The Allsteel on December 11\, 2019\, in Boston. Join us for a night of wine\, chocolate\, and cheer as we bid farewell to 2019 and look ahead to another successful year in the hub! \nTo register\, visit: https://www.womeninbio.org/events/EventDetails.aspx?id=1296476&group= \nProgram \n5:30 p.m. – Registration opens\n5:30 p.m. – 8:30 p.m.: Food\, drinks\, and networking \nPricing Information* \n\nMembers: $15\nNon-Members/Free Unlimited Guest Members*: $30\n\n*To access the Member rate\, click here to purchase a WIB membership. \nSpecial Pricing for Guests \nMembers can register guests at member price. \nWalk-Ins Accepted? \nYes* \n* – Walk-ins will be accepted until event capacity is reached \nMaximum Capacity \n60 \nParking Information \nParking available at State Street garage and other nearby garages. \nDirections from Public Transit \nRed line to State Street
URL:https://scienceinboston.com/event/women-in-bio-2019-annual-wine-chocolate-holiday-party-2/
LOCATION:Allsteel\, 200 State Street #400\, Boston\, MA\, 02109\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191212T081500
DTEND;TZID=America/New_York:20191212T160000
DTSTAMP:20260715T042319
CREATED:20191125T160803Z
LAST-MODIFIED:20191125T160803Z
UID:7343-1576138500-1576166400@scienceinboston.com
SUMMARY:Live-Stream at M2D2: The Massachusetts Conference for Women
DESCRIPTION:Overview\n\nCome join us at M2D2 for a Live-Stream of the Massachusetts Conference for Women! \nThe Massachusetts Conference for Women provides one full day of connection\, motivation\, networking\, inspiration and skill building for thousands of women each year. Since the first Conference in 2005\, this annual event has grown to a sold-out crowd of more than 10\,000 attendees and impacts thousands of lives. Dozens of expert speakers lead workshops and seminars on the issues that matter most to women\, including personal finance\, business and entrepreneurship\, health\, work/life balance and more. The Conference offers incredible opportunities for business networking\, professional development and personal growth.
URL:https://scienceinboston.com/event/live-stream-at-m2d2-the-massachusetts-conference-for-women/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191212T081500
DTEND;TZID=America/New_York:20191212T160000
DTSTAMP:20260715T042319
CREATED:20191125T160803Z
LAST-MODIFIED:20191125T160803Z
UID:27407-1576138500-1576166400@scienceinboston.com
SUMMARY:Live-Stream at M2D2: The Massachusetts Conference for Women
DESCRIPTION:Overview\n\nCome join us at M2D2 for a Live-Stream of the Massachusetts Conference for Women! \nThe Massachusetts Conference for Women provides one full day of connection\, motivation\, networking\, inspiration and skill building for thousands of women each year. Since the first Conference in 2005\, this annual event has grown to a sold-out crowd of more than 10\,000 attendees and impacts thousands of lives. Dozens of expert speakers lead workshops and seminars on the issues that matter most to women\, including personal finance\, business and entrepreneurship\, health\, work/life balance and more. The Conference offers incredible opportunities for business networking\, professional development and personal growth.
URL:https://scienceinboston.com/event/live-stream-at-m2d2-the-massachusetts-conference-for-women-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191212T170000
DTEND;TZID=America/New_York:20191212T200000
DTSTAMP:20260715T042319
CREATED:20191125T161144Z
LAST-MODIFIED:20191125T161144Z
UID:7345-1576170000-1576180800@scienceinboston.com
SUMMARY:2019 Annual Holiday Party
DESCRIPTION:Winter is in the air! And with cold weather and sweaters comes MassBio’s most anticipated mixer of the year – our 2019 Annual Holiday Party. \nKick off the season with MassBio at our holiday celebration at the Hyatt Regency on December 12. This premier event gathers 800+ guests from MassBio’s member companies. Bring a colleague or make a few new friends while celebrating the holiday season. \nThis event is members only.
URL:https://scienceinboston.com/event/2019-annual-holiday-party/
LOCATION:Hyatt Regency Cambridge\, 575 Memorial Drive\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191212T170000
DTEND;TZID=America/New_York:20191212T200000
DTSTAMP:20260715T042319
CREATED:20191125T161144Z
LAST-MODIFIED:20191125T161144Z
UID:27408-1576170000-1576180800@scienceinboston.com
SUMMARY:2019 Annual Holiday Party
DESCRIPTION:Winter is in the air! And with cold weather and sweaters comes MassBio’s most anticipated mixer of the year – our 2019 Annual Holiday Party. \nKick off the season with MassBio at our holiday celebration at the Hyatt Regency on December 12. This premier event gathers 800+ guests from MassBio’s member companies. Bring a colleague or make a few new friends while celebrating the holiday season. \nThis event is members only.
URL:https://scienceinboston.com/event/2019-annual-holiday-party-2/
LOCATION:Hyatt Regency Cambridge\, 575 Memorial Drive\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191216T090000
DTEND;TZID=America/New_York:20191217T163000
DTSTAMP:20260715T042319
CREATED:20191125T161328Z
LAST-MODIFIED:20191125T161646Z
UID:7348-1576486800-1576600200@scienceinboston.com
SUMMARY:Biotech 101: The Science & Business of Biotech\, Dec 2019
DESCRIPTION:Overview\n\nNew to the life sciences industry? Do you need to have a better understanding of the science and business models driving the industry? Biotech 101: The Science of Biotech & The Business of Biotech provides a thorough overview of the industry at a reduced cost. The program covers two full days of biotechnology information for non-science professionals who may be working or looking to work in the biopharmaceutical industry. \nTarget Audience:\n\nNon-science professionals from all sectors of the biotech\, pharma\, and life sciences industries\, including: sales\, marketing\, HR\, legal\, manufacturing\, business development\, finance\, management\, government relations\, IT\, safety\, tech transfer offices\nPatient advocacy groups\, disease foundations\nPolicy makers\, lobbyists\, attorneys\nVenture capitalists\, angel investors\, banks\, analysts\, financial managers\nInsurance brokers\, real estate professionals\nConsultants\, public relations specialists\, journalists\nUniversity administrators\, research institute support staff\nEnvironmental & Health & Safety Engineers\n\nDay 1 \nWhat is the science behind biotechnology? Explore the key concepts on which the industry is built through hands-on activities and simple lab techniques. This program is designed to provide non-science professionals with a better understanding of the molecular biology that drives the production of most biopharmaceutical products and to help them better understand the research activities in their organizations. \nIn this course you will learn: How medicines made through biotechnology differ from other medicines\, what DNA does\, how the body makes proteins\, how genetic engineering works\, what personalized medicine is\, and how proteins are made in the lab.  Participants will perform agarose gel electrophoresis and protein purification. \nDay 2 \nThe Business of Biotech explores the business considerations that drive company strategies. Gain a deeper understanding of how companies are funded\, which government agencies regulate the sector and how different departments need to be aligned to be successful. This day provides an overview of how the industry works\, why it works the way it does\, and how the industry may change in the years ahead. For those considering careers in the biopharma space or transitioning from the science and technical aspects of the industry to the business side\, this course delivers a sound\, basic understanding of the “business of biotech”. \nCourse content includes: From Discovery to Commercialization\, Role of Non-profit Basic Research\, Intellectual Property Considerations & Funding Sources\, Organizational Characteristics\, and The Ecosystem and the Future of Biopharma \nInstructors:\nMichelle Mischke\, PhD is the Director of Biotechnology Education Programs at MassBioEd. She has extensive research\, teaching\, and administrative experience. She taught a range of undergraduate biology courses at MIT and was a course coordinator and content developer for 7.00x\, the first large online biology course offered by edX. While at MIT\, she was involved in K-12 science outreach and education programs. Michelle holds a B.A. in both Biology and Chemistry from Colorado State University and a Ph.D. in Pharmacology from the University of Medicine and Dentistry of New Jersey. Prior to joining the Department of Biology at MIT\, she worked as a postdoctoral fellow at Harvard University. \nImran Nasrullah\, MS\, JD\, CLP has twenty years of experience in biopharmaceutical business development\, licensing\, and economic development experience. Currently he serves as Director of Innovation Sourcing at Boehringer Ingelheim\, where he facilitates access to new scientific innovation emerging from the Boston area and forges business relationships within the Boston Cambridge life-science ecosystem. He served on the Senior Advisory Board for Cellanyx after heading strategic alliances and business development for T1D First\, a disease foundation dedicated to curing Type 1 Diabetes. As Head of Strategic Alliances\, he led industry\, academic and not-for-profit partnerships. Prior to T1D First\, Imran served as CBO at MassBio\, where he built MassBio’s business & investor and economic development outreach programs – known as MassBio Innovation Services – to help companies raise capital and identify strategic partnering and licensing opportunities. Up until then\, Imran worked for ten years in the biopharmaceutical industry as directors of business development and licensing for Genzyme Corporation\, Millennium Pharmaceuticals. Imran started his licensing career working for Mayo Clinic and then later\, the Dana Farber Cancer Institute. Imran is author to several publications regarding the impact of exercise on auto-immune disease patients. He received the 2010 Outstanding 50 Asian American Business awardee. Imran received his MS in Physiology at the University of Colorado and his BS in Exercise Physiology at the University of Massachusetts Amherst. He holds a JD in Intellectual Property and Licensing from Suffolk University Law School.
URL:https://scienceinboston.com/event/biotech-101-the-science-business-of-biotech-dec-2019/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191216T090000
DTEND;TZID=America/New_York:20191217T163000
DTSTAMP:20260715T042319
CREATED:20191125T161328Z
LAST-MODIFIED:20191125T161328Z
UID:27409-1576486800-1576600200@scienceinboston.com
SUMMARY:Biotech 101: The Science & Business of Biotech\, Dec 2019
DESCRIPTION:Overview\n\nNew to the life sciences industry? Do you need to have a better understanding of the science and business models driving the industry? Biotech 101: The Science of Biotech & The Business of Biotech provides a thorough overview of the industry at a reduced cost. The program covers two full days of biotechnology information for non-science professionals who may be working or looking to work in the biopharmaceutical industry. \nTarget Audience:\n\nNon-science professionals from all sectors of the biotech\, pharma\, and life sciences industries\, including: sales\, marketing\, HR\, legal\, manufacturing\, business development\, finance\, management\, government relations\, IT\, safety\, tech transfer offices\nPatient advocacy groups\, disease foundations\nPolicy makers\, lobbyists\, attorneys\nVenture capitalists\, angel investors\, banks\, analysts\, financial managers\nInsurance brokers\, real estate professionals\nConsultants\, public relations specialists\, journalists\nUniversity administrators\, research institute support staff\nEnvironmental & Health & Safety Engineers\n\nDay 1 \nWhat is the science behind biotechnology? Explore the key concepts on which the industry is built through hands-on activities and simple lab techniques. This program is designed to provide non-science professionals with a better understanding of the molecular biology that drives the production of most biopharmaceutical products and to help them better understand the research activities in their organizations. \nIn this course you will learn: How medicines made through biotechnology differ from other medicines\, what DNA does\, how the body makes proteins\, how genetic engineering works\, what personalized medicine is\, and how proteins are made in the lab.  Participants will perform agarose gel electrophoresis and protein purification. \nDay 2 \nThe Business of Biotech explores the business considerations that drive company strategies. Gain a deeper understanding of how companies are funded\, which government agencies regulate the sector and how different departments need to be aligned to be successful. This day provides an overview of how the industry works\, why it works the way it does\, and how the industry may change in the years ahead. For those considering careers in the biopharma space or transitioning from the science and technical aspects of the industry to the business side\, this course delivers a sound\, basic understanding of the “business of biotech”. \nCourse content includes: From Discovery to Commercialization\, Role of Non-profit Basic Research\, Intellectual Property Considerations & Funding Sources\, Organizational Characteristics\, and The Ecosystem and the Future of Biopharma \nInstructors:\nMichelle Mischke\, PhD is the Director of Biotechnology Education Programs at MassBioEd. She has extensive research\, teaching\, and administrative experience. She taught a range of undergraduate biology courses at MIT and was a course coordinator and content developer for 7.00x\, the first large online biology course offered by edX. While at MIT\, she was involved in K-12 science outreach and education programs. Michelle holds a B.A. in both Biology and Chemistry from Colorado State University and a Ph.D. in Pharmacology from the University of Medicine and Dentistry of New Jersey. Prior to joining the Department of Biology at MIT\, she worked as a postdoctoral fellow at Harvard University. \nImran Nasrullah\, MS\, JD\, CLP has twenty years of experience in biopharmaceutical business development\, licensing\, and economic development experience. Currently he serves as Director of Innovation Sourcing at Boehringer Ingelheim\, where he facilitates access to new scientific innovation emerging from the Boston area and forges business relationships within the Boston Cambridge life-science ecosystem. He served on the Senior Advisory Board for Cellanyx after heading strategic alliances and business development for T1D First\, a disease foundation dedicated to curing Type 1 Diabetes. As Head of Strategic Alliances\, he led industry\, academic and not-for-profit partnerships. Prior to T1D First\, Imran served as CBO at MassBio\, where he built MassBio’s business & investor and economic development outreach programs – known as MassBio Innovation Services – to help companies raise capital and identify strategic partnering and licensing opportunities. Up until then\, Imran worked for ten years in the biopharmaceutical industry as directors of business development and licensing for Genzyme Corporation\, Millennium Pharmaceuticals. Imran started his licensing career working for Mayo Clinic and then later\, the Dana Farber Cancer Institute. Imran is author to several publications regarding the impact of exercise on auto-immune disease patients. He received the 2010 Outstanding 50 Asian American Business awardee. Imran received his MS in Physiology at the University of Colorado and his BS in Exercise Physiology at the University of Massachusetts Amherst. He holds a JD in Intellectual Property and Licensing from Suffolk University Law School.
URL:https://scienceinboston.com/event/biotech-101-the-science-business-of-biotech-dec-2019-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191218T080000
DTEND;TZID=America/New_York:20191218T100000
DTSTAMP:20260715T042319
CREATED:20191125T161607Z
LAST-MODIFIED:20191125T161607Z
UID:7351-1576656000-1576663200@scienceinboston.com
SUMMARY:Fireside Chat with Stiris Research’s Experts on Health Authority Inspection
DESCRIPTION:Description\nHealth authority inspections evoke reactions that are situated somewhere on the spectrum between panic to preparedness. Between innovative studies\, collaborating with vendors\, and supporting your clinical trial sites\, there is a multitude of scenarios where you may find yourself questioning your inspection preparedness. Organizations want to know: where can things go wrong and how do we set ourselves up for the best results? \nStiris’ QA Expert\, Kara Lee McWatters\, and President & CEO\, Shantal Feltham\, will discuss common findings from health authority inspections\, how to avoid pitfalls during an inspection\, day-to-day strategies you can implement\, challenges\, successes\, and real-life anecdotes to help you be inspection ready. Following the fireside chat\, there will be an open Q&A forum\, where you’ll have the opportunity to dig deeper into the information provided or ask your own questions. \nWant to guarantee your inspection question gets addressed? Submit ALL your questions via email at Auditing@StirisResearch.com or on Twitter @StirisResearch. \nStiris Research is a MassBIO member. MassBio Forums are networking and professional development that is planned for members by members to discuss industry hot topics\, tackle common challenges and share best practices. For those who cannot make it to Cambridge\, MassBio also webcasts all presentations live and archives the videos for on-demand replay in the Knowledge Base. See massbio.org for more information
URL:https://scienceinboston.com/event/fireside-chat-with-stiris-researchs-experts-on-health-authority-inspection/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191218T080000
DTEND;TZID=America/New_York:20191218T100000
DTSTAMP:20260715T042319
CREATED:20191125T161607Z
LAST-MODIFIED:20191125T161607Z
UID:27410-1576656000-1576663200@scienceinboston.com
SUMMARY:Fireside Chat with Stiris Research’s Experts on Health Authority Inspection
DESCRIPTION:Description\nHealth authority inspections evoke reactions that are situated somewhere on the spectrum between panic to preparedness. Between innovative studies\, collaborating with vendors\, and supporting your clinical trial sites\, there is a multitude of scenarios where you may find yourself questioning your inspection preparedness. Organizations want to know: where can things go wrong and how do we set ourselves up for the best results? \nStiris’ QA Expert\, Kara Lee McWatters\, and President & CEO\, Shantal Feltham\, will discuss common findings from health authority inspections\, how to avoid pitfalls during an inspection\, day-to-day strategies you can implement\, challenges\, successes\, and real-life anecdotes to help you be inspection ready. Following the fireside chat\, there will be an open Q&A forum\, where you’ll have the opportunity to dig deeper into the information provided or ask your own questions. \nWant to guarantee your inspection question gets addressed? Submit ALL your questions via email at Auditing@StirisResearch.com or on Twitter @StirisResearch. \nStiris Research is a MassBIO member. MassBio Forums are networking and professional development that is planned for members by members to discuss industry hot topics\, tackle common challenges and share best practices. For those who cannot make it to Cambridge\, MassBio also webcasts all presentations live and archives the videos for on-demand replay in the Knowledge Base. See massbio.org for more information
URL:https://scienceinboston.com/event/fireside-chat-with-stiris-researchs-experts-on-health-authority-inspection-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260715T042319
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:7524-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260715T042319
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:27419-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-3/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
END:VCALENDAR